Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07059065 · ClinicalTrials.gov registry record · NA
FIBERGRAFT Aeridyan Posterolateral Fusion Study
A NA study of Degenerative Spine Disease, sponsored by DePuy Synthes Products.
- Recruiting
- Registry status
- NA
- Development phase
- 316
- Enrollment target
- 7
- Study locations
NCT07059065: Recruiting NA study of Degenerative Spine Disease, sponsored by DePuy Synthes Products.
NCT07059065 is a NA study of Degenerative Spine Disease that is actively recruiting participants, run by DePuy Synthes Products. The registered enrollment target is 316 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07059065, a NA study of Degenerative Spine Disease, is actively recruiting participants, sponsored by DePuy Synthes Products.
- RECRUITING
- Registry status
- NA
- Development phase
- 316 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a post-market, prospective, controlled, multicenter clinical study to evaluate radiographic fusion and clinical outcomes of FIBERGRAFT™ Aeridyan Matrix bone graft substitute in subjects who undergo a 1-3 level instrumented lumbar posterolateral fusion surgery. This clinical study will be conducted at up to 10 clinical sites within the United States.
Primary Outcome
FIBERGRAFT Aeridyan Matrix percent levels fused at 12 months compared to the grafting control in the posterolateral lumbar spine
Conditions Studied
Interventions
- DEVICE FIBERGRAFT™ Aeridyan Matrix Bone Graft Substitute
- DEVICE Demineralized Bone Matrix
Study Locations (7)
California
- UC Davis Health System - Sacramento
Illinois
- University Of Illinois - Chicago
Kentucky
- UK Health Care Kentucky Neuroscience Institute - Lexington
Massachusetts
- Brigham And Women's Hospital - Boston
North Carolina
- Duke University Medical Center - Durham
Pennsylvania
- Rothman Orthopaedics Institute - Philadelphia
Texas
- UT Health Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 316 participants |
| Start Date | 2025-08-15 |
| Est. Completion | 2028-12-29 |
| Phase | NA |
What NCT07059065 shows while recruiting
NCT07059065 is an interventional study that assigns participants to a tested intervention. The registered 316 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Degenerative Spine Disease appearing as the primary indexed condition, and to 2 interventions - of which FIBERGRAFT™ Aeridyan Matrix Bone Graft Substitute is the first listed.
NCT07059065 lists 7 locations in 7 states (California, Illinois, Kentucky).
Frequently Asked Questions
What is clinical trial NCT07059065 about?
NCT07059065 is a clinical study titled "FIBERGRAFT Aeridyan Posterolateral Fusion Study". This is a post-market, prospective, controlled, multicenter clinical study to evaluate radiographic fusion and clinical outcomes of FIBERGRAFT™ Aeridyan Matrix bone graft substitute in subjects who undergo a 1-3 level instrumented lumbar posterolateral fusion surgery. This clinical study will be con...
What is the current status of trial NCT07059065?
This trial is currently recruiting. It is a NA study. The enrollment target is 316 participants. The study started on 2025-08-15. Estimated completion is 2028-12-29.
What conditions does trial NCT07059065 study?
This clinical trial studies the following conditions: Degenerative Spine Disease.
What interventions are being tested in trial NCT07059065?
The interventions under investigation include: FIBERGRAFT™ Aeridyan Matrix Bone Graft Substitute (DEVICE), Demineralized Bone Matrix (DEVICE).
Who is sponsoring clinical trial NCT07059065?
This trial is sponsored by DePuy Synthes Products, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07059065 being conducted?
This trial has 7 study locations across California, Illinois, Kentucky, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07059065's enrollment target sits among peer trials
316 321st of 2000 higher than 1,679 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04256317 · 316 participants · Phase 2
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- NCT04787042 · 316 participants · Phase 1
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- NCT04802759 · 316 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- NCT05464056 · 316 participants · NA
BUILT Family Lifestyle Program for Children with ADHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI